Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00172094 | Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches | PHASE2 | COMPLETED | 189 | — | — | Dec 31, 2003 | Jul 31, 2004 | Jun 3, 2021 | 22 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | PLACEBO |
| 2 | EXPERIMENTAL | 400 mg 1776 powder |
| 3 | EXPERIMENTAL | 1776 (800 mg) |
| Name | Type | Description |
|---|---|---|
| NPS 1776 (800 mg) | DRUG | NPS 1776 (800 mg) powder |
| PLACEBO | DRUG | Placebo in non-carbonated fruit flavored drink (150 ml) |
| NPS 1776 (400 mg) | DRUG | NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink |
Inclusion Criteria: 1. Diagnosis of migraine for at least a year prior to screening. 2. Experiences 2-10 migraine headaches per month (with at least 24 hours between episodes) and no more than 15 headache days per month in the 3 months prior to screening. 3. Ability and willingness to arrive at the...